These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent. Hussain SA; Tsao J; Li M; Schwarz MD; Zhou R; Wu JY; Salamon N; Sankar R Epilepsia; 2017 Apr; 58(4):674-682. PubMed ID: 28230253 [TBL] [Abstract][Full Text] [Related]
6. Vigabatrin Toxicity in a Patient with Infantile Spasms Treated with Concomitant Hormonal Therapy. Lotan E; Bluvstein J; Zan E Isr Med Assoc J; 2020 Jul; 22(7):461-462. PubMed ID: 33236576 [No Abstract] [Full Text] [Related]
7. Vigabatrin administration in patients with infantile spasms: the risks. Jaseja H Clin Neurol Neurosurg; 2010 Nov; 112(9):835. PubMed ID: 20934097 [No Abstract] [Full Text] [Related]
8. Are vigabatrin induced T2 hyperintensities in cranial MRI associated with acute encephalopathy and extrapyramidal symptoms? Dill P; Datta AN; Weber P; Schneider J Eur J Paediatr Neurol; 2013 May; 17(3):311-5. PubMed ID: 23199677 [TBL] [Abstract][Full Text] [Related]
9. Reversible magnetic resonance imaging and spectroscopy abnormalities in the course of vigabatrin treatment for West syndrome. Thelle T; Gammelgaard L; Hansen JK; Østergaard JR Eur J Paediatr Neurol; 2011 May; 15(3):260-4. PubMed ID: 20926323 [TBL] [Abstract][Full Text] [Related]
10. An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms. Fong CY; Osborne JP; Edwards SW; Hemingway C; Hancock E; Johnson AL; Kennedy CR; Kneen R; Likeman M; Lux AL; Mordekar SR; Murugan V; Newton RW; Pike M; Quinn M; Spinty S; Vassallo G; Verity CM; Whitney A; O'Callaghan FJ Dev Med Child Neurol; 2013 Sep; 55(9):862-7. PubMed ID: 23789722 [TBL] [Abstract][Full Text] [Related]
11. Brain MRI findings with vigabatrin therapy: case report and literature review. Hussain K; Walsh TJ; Chazen JL Clin Imaging; 2016; 40(1):180-2. PubMed ID: 26526789 [TBL] [Abstract][Full Text] [Related]
12. Vigabatrin therapy in infantile spasms: solving one problem and inducing another? Wohlrab G; Leiba H; Kästle R; Ramelli G; Schmitt-Mechelke T; Schmitt B; Landau K Epilepsia; 2009 Aug; 50(8):2006-8. PubMed ID: 19682036 [No Abstract] [Full Text] [Related]
14. Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study. Akula JD Neurology; 2015 Aug; 85(7):655-6. PubMed ID: 26283761 [No Abstract] [Full Text] [Related]
15. Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration. Horton M; Rafay M; Del Bigio MR J Child Neurol; 2009 Dec; 24(12):1543-6. PubMed ID: 19773459 [TBL] [Abstract][Full Text] [Related]
17. Analysis of vigabatrin treatment causing visual field defects in infantile spasms. Chiron C; Dulac O Dev Med Child Neurol; 2015 Jan; 57(1):9-10. PubMed ID: 25109842 [No Abstract] [Full Text] [Related]
18. The vigabatrin-associated brain abnormalities on MRI and their differential diagnosis. Corrêa DG; Telles B; Freddi TAL Clin Radiol; 2024 Feb; 79(2):94-101. PubMed ID: 38092645 [TBL] [Abstract][Full Text] [Related]
19. Reversible MRI Changes in an Infant with Epileptic Spasms on Low Dose Vigabatrin. Jain P; Alwadhi R; Kumar V Indian J Pediatr; 2016 Sep; 83(9):1049-50. PubMed ID: 26817464 [No Abstract] [Full Text] [Related]
20. Efficacy and safety of vigabatrin in Japanese patients with infantile spasms: Primary short-term study and extension study. Ohtsuka Y Epilepsy Behav; 2018 Jan; 78():134-141. PubMed ID: 29190579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]